Evoke Pharma (EVOK) Appoints Ben Smeal to its Board

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company’s Board of Directors effective October 18, 2024. This appointment fulfills a condition set as part of the company’s most recent financing by Nantahala Capital Management.

Mr. Smeal brings extensive experience in investment management and corporate governance. Before transitioning to full-time private investing, he held roles at Willett Advisors, the family office of Michael R. Bloomberg, and Kenmare Management, a multi-million-dollar hedge fund, where he gained unique insights into strategic business development and equity investments. Additionally, his role as Marketing Director at Overstock.com, a leading online retailer, gave him significant experience in both traditional and digital marketing, enhancing his ability to drive growth and innovation. Mr. Smeal has served on multiple corporate boards and holds a B.A. in Political Economy from Williams College and an M.B.A. from Columbia University.

“We are thrilled to welcome Ben to our board,” said Matt D'Onofrio, CEO of Evoke Pharma. “His extensive experience in public equities, coupled with a strong background in corporate leadership and strategic insights, will be invaluable as we work to expand access to GIMOTI for patients in need.”

Ben Smeal expressed his enthusiasm, stating, “I am honored to join Evoke’s Board of Directors. The company’s unwavering dedication to improving patient outcomes in such an underserved area of medicine resonates deeply with me, and I look forward to working with the team to drive future success.”

You May Also Be Interested In

• BofA Securities Reinstates Zoom Video (ZM) at Buy
• Vision Marine and Avikus begin electric boat navigation integration
• OSR Health faces Nasdaq delisting risk after missing $1 bid threshold